EUCTR2020-001748-24-SE进行中（未招募）1 期
A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study.
Karolinska University Hospital0 个研究点目标入组 120 人开始时间: 2020年4月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Age =18 years
- •2)Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay < 3 days prior to screening
- •3)SARS-CoV-2 infection with duration at least 7 days (as determined by onset of symptoms)
- •4)5 liters/minute of Oxygen for at least 8 hours to maintain SpO2 at =93% . A shorter duration is also accepted if presentation is acute, and the patient needs more than 10 l liters/minute of Oxygen to maintain SpO2 at =93%.
- •5)CRP > 70 mg/L with no non-SARS-Cov2 infections. Values measured up to 48 hours before inclusion are accepted.
- •6)Ferritin > 500 µg/L. Values measured up to 48 hours before inclusion are accepted.
- •7)At least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/L; D-dimer = 0.5 mg/L and; Lactate Dehydrogenase = 8 microkatal/L. The values do not have to be concurrently positive and may be up to 3 days old at inclusion.
- •8)Ability to provide informed consent signed by study patient
- •9)Willingness and ability to comply with study-related procedures/assessments
- •10)In fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. These may include birth control pills, surgical sterilization of patient or partner, intrauterine device or condoms, but not birth control pills which may increase risk of deep venous thrombosis during COVID infections. Non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an FSH level in the postmenopausal range.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •1)Pregnancy or breast feeding.
- •2)Ongoing or completed mechanical ventilation.
- •3)In the opinion of the investigator, unlikely to survive for >48 hours from screening.
- •4)In the opinion of the investigator, expected overall survival due to other comorbidities less than 3 months.
- •5)Severe renal dysfunction eGFR < 30 ml/min.
- •6)Medical history including chronic liver disease with inflammation, fibrosis or cirrhosis including underlying diseases such as alcoholic liver disease, non-alcoholic fatty liver disease, chronic viral hepatitis, alcoholic liver disease, autoimmune liver disease, hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, cholangitis, or carcinoma.
- •7)Uncontrolled hypertension Systolic BP >180 mm Hg, Diastolic BP > 110 mm Hg
- •8)History of hypersensitivity to the study drugs
- •9)Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 2 x 109/L, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5 x upper limit of normal (ULN), platelets <100 x 109/L
- •10)Treatment with anakinra, anti-IL 6, anti-IL-6R antagonists, Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period
- •11)Current treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents
- •12)Use of chronic oral corticosteroids for a non-COVID-19-related condition in a dose higher than prednisone 10 mg or equivalent per day. Ongoing acute treatment for COVID-19 with any peroral or iv steroid is permitted for up to five days before inclusion. Chronic or acute treatment with inhaled steroids is also permitted.
- •13)History of, or current autoimmune or inflammatory systemic or localized disease(s) other than rheumatoid arthritis
- •14)Acute systemic infection; verified by blood cultures systemic bacterial infection, systemic fungi-infection or prosthesis-related infection
- •15)History of stem-cell or solid organ transplantation
- •16)Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections
- •17)Diagnosis of, or suspicion of HIV infection, acute hepatitis A and/or chronic hepatitis B and/or C
- •18)Previous history of gastrointestinal ulceration or diverticulitis.
- •19)Patients who have received immunosuppressive antibody therapy within the past 3 months, including intravenous immunoglobulin or plans to receive during the study period
- •20)Participation in any clinical research study evaluating an investigational product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit. The use of remdesivir is permitted.
- •21)Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study
研究者
相似试验
进行中（未招募）
不适用
Multicenter, prospective, open label study , in patients with non small celllung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of firstline chemotherapy in which it's possible a treatment that evaluates theeffectiveness and the safety of oral BIBF 1120 in combination withstandard docetaxel therapy, which can be administered (at the discretionof the referring physician) with tri-weekly or weekly scheduleon Small Cell Lung Cancer stage IIB/IV or recurrentEUCTR2014-005016-42-ITDipartimento di Oncologia-Università degli studi di Torino180
进行中（未招募）
1 期
A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.Renal TransplantEUCTR2005-003383-39-ESRoche Farma S.A.144
进行中（未招募）
1 期
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia.EUCTR2006-000914-19-GBJanssen-Cilag International N.V.
进行中（未招募）
1 期
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia.Anemia in cancer patients receiving chemotherapyMedDRA Version 5.1: list of preferred terma used in the process of defining thrombotic vascular events, see investigator's brochure epoetin alphaEUCTR2006-000914-19-FRJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
进行中（未招募）
不适用
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia. - NDEUCTR2006-000914-19-ITJANSSEN-CILAG INTERNATIONAL NV500